Amgen bought ChemoCentryx ChemoCentryx from 10/20/22

User image

Vladimir Petenev

News editor
press@blackterminal.com

Amgen completed its acquisition of ChemoCentryx for $3.7 billion, or $52 per share.

ChemoCentryx

Review

Source:

{source} pictogram

investors.amgen.com

Vladimir Petenev

News editor

Write your comment first

News feed

Regeneron reported for 6 months of 2023

8/3/23 REGN

INARCTICA reported for 6 months of 2023 by RAS

8/3/23 AQUA

Moscow Exchange became first CFA exchange operator

8/3/23 MOEX

Beluga Group decided to change its name to NovaBev Group

8/3/23 BELU

VEON's revenues in the 1st half of the year decreased by 6.5%

8/3/23 VEON

Rostelecom reported for 6 months of 2023 by IFRS

8/3/23 RTKM

SPB Exchange summarized trading results in July

8/3/23 SPBE

Sberbank reported for 6 months of 2023 by IFRS

8/3/23 SBER

Beluga Group reported for 6 months of 2023 by RAS

8/3/23 BELU

Energy Transfer reported for 6 months of 2023

8/3/23 ET